Price
Target price
€19.71
€19.71
-3.020%
-0.615
-3.020%
€60.55
31.05.24 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
Heavy losses for Intellia Therapeutics Inc today as the stock fell by -€0.615 (-3.020%).
With 13 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 60 € there is potential for a 204.41% increase which would mean more than doubling the current price of 19.71 € for Intellia Therapeutics Inc.
So far the community has only identified positive things for Intellia Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -3.020% | -13.968% | -1.696% | -43.443% | -31.917% | -67.847% | 57.680% |
| Chromadex Corp | 3.150% | -8.333% | -18.012% | 100.000% | 97.015% | -61.176% | - |
| Organovo Holdings Inc. | 2.430% | -2.061% | -9.519% | -43.421% | -11.988% | -87.630% | -91.147% |
| VBI Vaccines Inc. | -9.870% | -8.489% | 3.654% | -80.037% | 1.698% | -99.302% | -98.967% |
Comments
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at BMO Capital Markets from $62.00 to $70.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood can't seem to string together back-to-back years of success. The Ark Invest co-founder and CEO became a rock star among aggressive growth investors in 2020, only to see her
2 Stocks Down 30% to Buy Right Now
The bull market is roaring higher, and many growth stocks have led the gains -- but this doesn't mean your opportunity to buy growth stocks for a good price is over. Plenty of players with great
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
Cathie Wood is known for her investments in disruptive technologies that are changing or have the potential to change the way things are done. She's built a solid reputation as a stock picker